Valneva SE (FR:VLA)
:VLA
Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.59
-€0.05(-2.40%)
At close: 4:00 PM EST
€2.59
-€0.05(-2.40%)
Day’s Range― - ―
52-Week Range€2.14 - €5.42
Previous CloseN/A
Volume233.04K
Average Volume (3M)1.29M
Market Cap
€467.86M
Enterprise Value€568.12M
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.60Price Target Upside116.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€156.54M
Bulls Say, Bears Say
Bulls Say
First‑in‑class Lyme Vaccine (VLA15)VLA15 is the only advanced Lyme vaccine candidate in ~30 years with broad serotype coverage for North America and Europe, addressing a large unmet market. If approved, it provides durable competitive advantage, multi‑territory revenue potential and partner‑backed commercialization scale.
IXCHIQ Brazil Licensure & Local ManufacturingLocal licensure and manufacturing in Brazil create sustainable market access in endemic regions, reduce reliance on external suppliers, and support scalable rollout in a high‑need market. This strengthens durable revenue streams and supply resilience in key territories.
Restructuring And Expense DisciplineA decisive cost program and visible reductions in SG&A align spending with priorities, materially lowering cash burn and improving operating leverage. These structural actions extend runway and increase the firm's ability to fund pivotal launches and regulatory filings.
Bears Say
Persistent Negative Cash FlowSustained negative OCF and FCF signal the business consumes cash to operate and grow. This increases reliance on external financing, raising dilution or covenant risk and constraining investment in manufacturing scale‑up and commercialization over the medium term.
Elevated Leverage And Shrinking EquityHigh debt versus a reduced equity base limits financial flexibility and raises refinancing and dilution risk if losses persist. Elevated leverage increases fixed costs, reduces headroom for strategic investments, and amplifies downside during revenue volatility.
Regulatory/manufacturing Constraint For U.S. SupplyAn FDA observation restricting a key facility creates durable operational risk: possible supply interruptions, higher production costs, and delayed U.S. market access. That raises execution risk for core product sales and can persist until regulatory remediation is complete.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.13 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €467.86M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 84 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Undervalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went up 1.897%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
VLA Stock 12 Month Forecast
Average Price Target
€5.60
▲(116.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---